Gabriele Minuti

2.9k total citations · 1 hit paper
35 papers, 911 citations indexed

About

Gabriele Minuti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gabriele Minuti has authored 35 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Gabriele Minuti's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Gabriele Minuti is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Gabriele Minuti collaborates with scholars based in Italy, United States and Malaysia. Gabriele Minuti's co-authors include Federico Cappuzzo, Lorenza Landi, Armida D’Incecco, Elisa Rossi, Carmelo Tibaldi, Antonio Chella, Gabriella Fontanini, Lucio Crinò, Luigi Terracciano and Roberto Incensati and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Gabriele Minuti

30 papers receiving 898 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

2014 492 citations Armida D’Incecco, Mariacarla Andreozzi et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gabriele Minuti Italy	12	665	515	229	164	119	35	911
Jinpeng Shi China	13	566 0.9×	446 0.9×	261 1.1×	169 1.0×	141 1.2×	27	840
Yuqi Wang China	10	389 0.6×	265 0.5×	222 1.0×	194 1.2×	174 1.5×	30	746
Xinmin Yu China	18	746 1.1×	704 1.4×	193 0.8×	217 1.3×	94 0.8×	48	1.1k
Bernadette Reyna Asuncion United States	9	425 0.6×	301 0.6×	147 0.6×	98 0.6×	180 1.5×	16	658
Vincent O’Neill United States	8	895 1.3×	620 1.2×	477 2.1×	303 1.8×	43 0.4×	28	1.2k
Ri-Qiang Liao China	11	917 1.4×	905 1.8×	314 1.4×	286 1.7×	233 2.0×	36	1.4k
Harald Hugenschmidt Norway	11	417 0.6×	189 0.4×	384 1.7×	267 1.6×	107 0.9×	13	826
Zhanhong Xie China	18	761 1.1×	519 1.0×	227 1.0×	172 1.0×	164 1.4×	60	1.1k
SL Moulder United States	8	620 0.9×	354 0.7×	180 0.8×	243 1.5×	202 1.7×	16	814
F. De Vita Italy	11	405 0.6×	196 0.4×	198 0.9×	220 1.3×	53 0.4×	37	691

Countries citing papers authored by Gabriele Minuti

Since Specialization

Citations

This map shows the geographic impact of Gabriele Minuti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriele Minuti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriele Minuti more than expected).

Fields of papers citing papers by Gabriele Minuti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriele Minuti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriele Minuti. The network helps show where Gabriele Minuti may publish in the future.

Co-authorship network of co-authors of Gabriele Minuti

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriele Minuti. A scholar is included among the top collaborators of Gabriele Minuti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriele Minuti. Gabriele Minuti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Avancini, Alice, Niccolò Giaj‐Levra, Gabriele Minuti, et al.. (2025). Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study. Lung Cancer. 203. 108531–108531.

Cortellini, Alessio, Sai Yendamuri, Eleni Karapanagiotou, et al.. (2025). 415P: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: Insights from the pembrolizumab 5-year global registry. Journal of Thoracic Oncology. 20(3). S241–S241.

Bria, Emilio, José Luís Costa, Claudio Sini, et al.. (2024). 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. Annals of Oncology. 35. S818–S818. 1 indexed citations

Mariotti, Sabrina, Gabriele Minuti, Lorenza Landi, et al.. (2024). Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary group. Heliyon. 10(23). e39324–e39324.

Cappuzzo, Federico, Lorenza Landi, Silvia Carpano, et al.. (2023). Pretreated EGFR/BRAF Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report. JTO Clinical and Research Reports. 4(8). 100545–100545.

Gallina, Filippo Tommaso, Fabiana Letizia Cecere, Lorenza Landi, et al.. (2023). ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma. Lung Cancer. 180. 107215–107215. 7 indexed citations

Landi, Lorenza, Angelo Delmonte, Andrea Bonetti, et al.. (2022). Combi-TED: A new Trial Testing Tedopi ^® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line. Future Oncology. 18(40). 4457–4464. 2 indexed citations

Minuti, Gabriele, Silvia Carpano, Ettore D’Argento, et al.. (2021). [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]. PubMed. 112(10). 639–646. 1 indexed citations

Lambertini, Matteo, Arlindo R. Ferreira, Antonio Di Meglio, et al.. (2017). Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. Clinical Breast Cancer. 17(8). 601–610.e2. 25 indexed citations

10.

D’Incecco, Armida, Marianna Gallo, Antonella De Luca, et al.. (2017). Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). Annals of Oncology. 28. vi62–vi62. 1 indexed citations

11.

Crinò, Lucio, Paolo Bidoli, Angelo Delmonte, et al.. (2016). Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population. Annals of Oncology. 27. iv3–iv3. 1 indexed citations

12.

Lambertini, Matteo, Arlindo R. Ferreira, Francesca Poggio, et al.. (2015). Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. The Oncologist. 20(8). 880–889. 22 indexed citations

13.

Gasparini, Pierluigi, Luciano Cascione, Lorenza Landi, et al.. (2015). microRNA classifiers are powerful diagnostic/prognostic tools in ALK- , EGFR- , and KRAS -driven lung cancers. Proceedings of the National Academy of Sciences. 112(48). 14924–14929. 64 indexed citations

14.

D’Incecco, Armida, Mariacarla Andreozzi, Vienna Ludovini, et al.. (2014). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer. 112(1). 95–102. 492 indexed citations breakdown →

15.

Re, Marzia Del, Lorenza Landi, Marcello Tiseo, et al.. (2014). Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. Journal of Clinical Oncology. 32(15_suppl). 11056–11056. 1 indexed citations

16.

Minuti, Gabriele, Armida D’Incecco, & Federico Cappuzzo. (2013). Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy. 13(10). 1401–1412. 38 indexed citations

17.

Landi, Lorenza, Gabriele Minuti, Armida D’Incecco, & Federico Cappuzzo. (2013). Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Current Opinion in Oncology. 25(2). 130–136. 29 indexed citations

18.

Zoratto, Federica, Fotios Loupakis, Chiara Cremolini, et al.. (2013). Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology. 24. iv15–iv15. 1 indexed citations

19.

Minuti, Gabriele, Federico Cappuzzo, Renata Duchnowska, et al.. (2012). Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. British Journal of Cancer. 107(5). 793–799. 93 indexed citations

20.

Maio, Ermelinda De, Carmelo Tibaldi, Armida D’Incecco, et al.. (2010). Consequences of targeted treatments for second-line therapy. Annals of Oncology. 21. vii234–vii240. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact